| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
81,510,000 |
| Market
Cap: |
1.77(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.69 - $45.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,016,735 |
1,088,642 |
1,249,399 |
1,617,862 |
| Total Sell Value |
$31,322,673 |
$33,197,856 |
$38,301,409 |
$55,212,492 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
9 |
12 |
17 |
40 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ciaramella Giuseppe |
President & CSO |
• – – |
2023-01-03 |
4 |
OE |
$0.67 |
$51,356 |
D/D |
53,729 |
149,691 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2022-12-30 |
4 |
OE |
$0.67 |
$3,015 |
D/D |
4,500 |
95,962 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2022-12-12 |
4 |
AS |
$42.30 |
$2,178,229 |
D/D |
(51,015) |
91,462 |
|
-31% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2022-12-12 |
4 |
OE |
$0.67 |
$48,713 |
D/D |
26,863 |
142,477 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2022-10-31 |
4 |
AS |
$44.93 |
$927,203 |
I/I |
(20,000) |
103,000 |
|
-23% |
|
| Evans John M. |
CEO |
• • – |
2022-10-31 |
4 |
AS |
$44.92 |
$1,389,225 |
D/D |
(30,000) |
1,058,520 |
|
-23% |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-09-06 |
4 |
S |
$54.25 |
$29,892 |
I/I |
(551) |
0 |
|
16% |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-09-06 |
4 |
A |
$0.00 |
$0 |
I/I |
551 |
551 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-09-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(25,620) |
0 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-08-05 |
4 |
S |
$60.50 |
$1,229,807 |
I/I |
(20,326) |
0 |
|
33% |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
I/I |
888,573 |
2,803,027 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-08-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,342,933) |
25,620 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2022-07-28 |
4 |
AS |
$64.88 |
$1,315,559 |
I/I |
(20,000) |
123,000 |
|
-32% |
|
| Evans John M. |
CEO |
• • – |
2022-07-28 |
4 |
AS |
$64.87 |
$1,972,523 |
D/D |
(30,000) |
1,088,520 |
|
-32% |
|
| Evans John M. |
CEO |
• • – |
2022-04-28 |
4 |
AS |
$36.98 |
$759,597 |
I/I |
(20,000) |
143,000 |
|
44% |
|
| Evans John M. |
CEO |
• • – |
2022-04-28 |
4 |
AS |
$36.59 |
$1,139,302 |
D/D |
(30,000) |
1,118,520 |
|
44% |
|
| Evans John M. |
CEO |
• • – |
2022-04-28 |
4 |
OE |
$1.03 |
$137,036 |
D/D |
59,450 |
1,148,520 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-04-13 |
4 |
S |
$50.01 |
$981,205 |
I/I |
(19,466) |
0 |
|
-16% |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-04-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,084,861 |
2,490,515 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-04-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,616,168) |
12,818 |
|
- |
|
| Burrell Terry-Ann |
CFO |
• – – |
2022-03-31 |
4 |
S |
$59.11 |
$105,630 |
D/D |
(1,787) |
38,278 |
|
-15% |
|
| Burrell Terry-Ann |
CFO |
• – – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
40,065 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2022-03-31 |
4 |
S |
$59.11 |
$370,088 |
D/D |
(6,261) |
1,089,070 |
|
-15% |
|
| Evans John M. |
CEO |
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
56,250 |
1,095,331 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2022-03-31 |
4 |
S |
$59.11 |
$109,885 |
D/D |
(1,859) |
115,614 |
|
-15% |
|
169 Records found
|
|
Page 3 of 7 |
|
|
0.52 (2.45%) 
